Purple Biotech (PPBT) highlights new CAPTN-3 IM1240 data with Mount Sinai

Rhea-AI Filing Summary

Purple Biotech Ltd. filed a report stating that it issued a press release titled “Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai.” The filing mainly serves to furnish this press release as an exhibit for U.S. investors. The update highlights new data related to Purple Biotech’s CAPTN-3 tri-specific antibody program, IM1240, developed in collaboration with the Icahn School of Medicine at Mount Sinai.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 09/04/2025 - 07:03 AM Learn about SEC filing dates

FAQ

What did Purple Biotech (PPBT) report in this Form 6-K?

Purple Biotech reported that it issued a press release titled “Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai.” The press release is attached as Exhibit 99.1.

What is the focus of Purple Biotech’s announcement about IM1240?

The announcement focuses on new data supporting the unique design of CAPTN-3 tri-specific antibody IM1240, a program that Purple Biotech is highlighting in its collaboration with the Icahn School of Medicine at Mount Sinai.

Which collaboration is mentioned in Purple Biotech’s 6-K filing?

The filing mentions a collaboration between Purple Biotech Ltd. and the Icahn School of Medicine at Mount Sinai related to the CAPTN-3 tri-specific antibody IM1240.

What exhibit is included with this Purple Biotech (PPBT) Form 6-K?

The Form 6-K includes Exhibit 99.1, which is the press release titled “Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai.”

Does this Purple Biotech Form 6-K contain financial or earnings data?

No financial or earnings data are presented in this Form 6-K; it primarily furnishes a press release about new data for CAPTN-3 tri-specific antibody IM1240.

Who signed the Purple Biotech Form 6-K?

The Form 6-K was signed on behalf of Purple Biotech Ltd. by Gil Efron, who is identified as the Chief Executive Officer.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of September 2025

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

Form 20-F ☒        Form 40-F ☐

Purple Biotech

On September 4, 2025, Purple Biotech Ltd. (the “Company” or the “Registrant”) issued a press release “Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai”, which is attached hereto as Exhibit 99.1.

Exhibit
99.1		Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

September 4, 2025	PURPLE BIOTECH LTD.
	By:	/s/ Gil Efron
		Gil Efron
		Chief Executive Officer

2